Want to join the conversation?
$VRTX said that the FDA has rejected its supplemental New Drug Application for the use of KALYDECO (ivacaftor) in people with cystic fibrosis ages two and older with one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator gene. $VRTX plans to meet with the FDA to determine an appropriate path forward.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.